TIP Appoints Arjen Kraaij as Deputy CEO
TIP, a portfolio company of I Squared Capital and one of the leading truck and trailer leasing, rental, maintenance and repair providers across Europe and Canada appoints Arjen Kraaij as Deputy CEO. This follows the successful acquisition and integration of two large industry leasing companies in Europe and Canada and will position TIP well for the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005745/en/
Arjen Kraaij, appointed Deputy CEO of TIP Trailer Services (Photo: Business Wire)
Arjen has been successful in the role of Chief Commercial Officer for TIP Trailer Services since 2017. Having been with the business for 23 years in positions of increasing responsibility, he brings a wealth of knowledge from across the full scope of the business.
“Arjen has been instrumental in TIP’s success over the past years and I am proud to announce his promotion to Deputy CEO and I am confident he will be very successful working with me to drive TIP on its future growth path.” Bob Fast, President and CEO TIP Trailer Services said.
Arjen’s experience working with all the regions in addition to his relationships with both suppliers and customers, provides him with a solid foundation upon which to take on the day-to-day leadership of business operations.
“I am honoured and excited to take on this new role and work closely with all regional VPs to strongly drive the business forward.” says Arjen Kraaij.
Arjen holds a MBA from Erasmus University, has been a member of the European Transport Board since 2006, and will continue to be based at the TIP Group Headquarters, located in Amsterdam, Netherlands.
Arjen’s new appointment is in effect as of January 1st, 2021.
Headquartered in Amsterdam, TIP is one of the leading providers of both equipment and services within Europe and Canada. Located in 18 countries, and offering over 140 service locations, TIP specializes in providing the transportation and logistics sector with leasing, rental, maintenance, and repairs through a wide selection of trailer equipment. For more information, please visit: https://www.tipeurope.com
Treasury and Investor Relations Director
T: +31 20 504 1677
M: +31 621 105358
VP Sales and Marketing
M: +31 613 114293
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mawi DNA’s Extractionless Sample Collection Technology Enables BioTech Africa Launch of Affordable COVID-19 Mass Testing Platform25.1.2021 15:00:00 CET | Press release
Mawi DNA Technologies’ iSWAB-Microbiome-EL sample collection technology enables BioTech Africa to implement and launch a new ultra-high throughput COVID-19 testing program. This breakthrough, in conjunction with the ProbeSure™ COVID-19 One Step RT-PCR Kit from 3CR Bioscience, is designed to scale up to a capacity of 200,000 tests per day. “We are extremely proud and humbled to be part of South Africa’s fight against COVID-19 through BioTech Africa’s mass testing efforts,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies. In addition, Dr. Jenny Leslie, COO of BioTech Africa, worked closely with Scilutions Labware and Hook Diagnostics to identify the best products and supplier partners who could provide reagents to streamline the testing workflow, but also scale to the projected numbers with minimal supply chain disruption. “For the sample collection step, Mawi DNA Technologies’ iSWAB-Microbiome-EL (‘Extractionless’) product was chosen for its multiple benefits. This
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-225.1.2021 14:13:00 CET | Press release
Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005376/en/ AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 (Photo: AchilleS Vaccines) The AchilleS antibody project ‘mAbCo19’ will now be further tested in the clinic, possibly leading to an emergency market authorization this summer. AchilleS is developing this new therapeutic in c
“Look for the WELL Health-Safety Seal” Public Awareness Campaign Launches, Featuring Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17 th U.S. Surgeon General Richard Carmona25.1.2021 14:00:00 CET | Press release
As the world continues to battle COVID-19 and communities strive to get back to business, it is more important than ever to raise confidence in the safety of buildings and shared spaces. Today, Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th Surgeon General Richard Carmona came together in a new integrated ad campaign to raise awareness about the importance of the WELL Health-Safety Rating, an evidence-based third-party designation to verify that a building or space has taken the necessary steps to prioritize the health and safety of their staff, visitors and other stakeholders. The ambassadors encourage people to look for buildings and spaces with the WELL Health-Safety seal on their windows or doors to feel more confident in their decision to go inside. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005216/en/ WELL Health-Safety Seal (Photo: Business
The Estée Lauder Companies Announces Supply Chain Leadership Updates25.1.2021 14:00:00 CET | Press release
TodayThe Estée Lauder Companies (NYSE:EL) announced that after nearly 13 years with the company, Gregory F. Polcer, Executive Vice President, Global Supply Chain, has made the decision to retire, effective July 1, 2021. He will be succeeded by Roberto Canevari, who will assume the role of Executive Vice President, Global Supply Chain, effective May 1, 2021. Roberto will report directly to Fabrizio Freda, President and Chief Executive Officer. Greg will work closely with Roberto over the next several months to support a smooth and successful transition. “Greg has led ELC’s Global Supply Chain with a great blend of strategic insight and innovative thinking,” said Mr. Freda. “He has evolved our Supply Chain organization into a truly integrated, state-of-the-art global network that touches all aspects of our business and drives tremendous value. He has also been instrumental in elevating and operationalizing our core principles of safety and sustainability, and has been an enthusiastic and
Everbridge Awarded Statewide Vaccine Distribution Deployment Across West Virginia; Everbridge Software Enables Governments, Hospitals and Businesses to Coordinate Rapid Delivery and Communications of COVID-19 Vaccine25.1.2021 13:30:00 CET | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced COVID-19 Shield™: Vaccine Distribution, an extension to its CEM platform offering risk insights, logistics awareness andvaccine appointment management to support the full spectrum of organizations that develop, manufacture, transport, distribute, regulate, and administer the coronavirus vaccine. The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for all residents, including vulnerable populations with special needs. Representing significant adoption for its vaccine distribution software, Everbridge announced the deployment of its CEM Platform to power the digital vaccination distribution system for a variety of municipalities and organizations, including the entire state population of West Virginia, and the County of Sarasota, Florida, among others. This press release features multimedia. View the ful
Velodyne Lidar LIVE! Webinar Series Explores Autonomy in Smarter Cities, Caves, Airports and Disaster Response25.1.2021 13:00:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a new digital learning series called Velodyne Lidar LIVE! that begins January 28, 2021 at 1:00 p.m. PST. The series kicks off with a conversation featuring Dr. Stefan Hrabar, CEO of Emesent, on how to address autonomous exploration in challenging inaccessible environments such as caves, civil construction works, telecommunications infrastructure and disaster response environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005104/en/ The Velodyne Lidar LIVE! digital learning series examines what’s happening in lidar and mobility to build a safer, more intelligent future. (Graphic: Velodyne Lidar, Inc.) To register for episodes of the free Velodyne Lidar LIVE! webinar series visit: https://velodynelidar.com/events/. Velodyne Lidar LIVE! looks at industry developments regarding the advancement of safer mobility and smarter autonomy. The 45-minute webinars fea
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT ® (Siltuximab for Injection) in China25.1.2021 13:00:00 CET | Press release
EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT® (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Siltuximab is a monoclonal antibody approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). iMCD is a rare, life-threatening and debilitating condition of the lymph nodes and related tissues. Siltuximab is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005360/en/ “The BLA acceptance of siltuximab for review, an importan